We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00765089
First Posted: October 2, 2008
Last Update Posted: February 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Lawrence Wei, University of Pittsburgh
  Purpose

Atrial Fibrillation (AF) is one of the most common postoperative complications after coronary artery bypass grafting (CABG). Postoperative AF produces a substantial impact on hospital resources with an estimated annual expenditure of over $1 billion. This includes the cost of pharmacological treatment and the cost of the increased length of stay. The incidence of AF is about 30-40% in CABG patients and increases with age of the patient. As the average age of the patient that undergoes CABG surgery is increasing, it is critical to find a way to prevent or reduce the incidence of this complication.

We propose a prospective, randomized, controlled study to determine the role of pulmonary vein isolation by bipolar ablation in the prevention or reduction of postoperative AF. The block- randomization plan will be used to maintain balance of the study and control arms throughout the study.


Condition Intervention Phase
Postoperative Atrial Fibrillation Procedure: Isolation of pulmonary veins with Bipolar radiofrequency ablation Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by Lawrence Wei, University of Pittsburgh:

Primary Outcome Measures:
  • Reduced incidence of Postoperative Atrial fibrillation [ Time Frame: 12 hours ]

Enrollment: 35
Study Start Date: December 2005
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pulmonary Vein isolation
Patients in this arm will receive pulmonary vein isolation during surgery
Procedure: Isolation of pulmonary veins with Bipolar radiofrequency ablation
No Intervention: Standard of care
Subjects in this arm will receive standard of care and no pulmonary vein isolation

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients who require an isolated elective CABG surgery on CPB.
  2. Both male and female patients of age 18 years to 90 years.

Exclusion Criteria:

  1. Pre existing atrial fibrillation or history of previous atrial fibrillation.
  2. Inability to provide informed consent.
  3. Pregnant or nursing patients.
  4. Reoperative sternotomy
  5. Emergency CABG surgery.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00765089


Locations
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15102
Sponsors and Collaborators
University of Pittsburgh
  More Information

Responsible Party: Lawrence Wei, Associate Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00765089     History of Changes
Other Study ID Numbers: 0508144
First Submitted: September 30, 2008
First Posted: October 2, 2008
Last Update Posted: February 12, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes